GREGoRi Innovation Projects (U01 Clinical Trial Optional)

National Institutes of Health · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$7.5M
Est. Value
October 30, 2026
Response Due
Active
Status

Opportunity Overview

The National Human Genome Research Institute (NHGRI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on proof of concept studies that explore novel strategies for identifying the gene(s) or variant(s) underlying rare genetic disorders, which take advantage of new and emerging molecular technologies. A primary goal of this initiative is to move beyond the current state of the art approach that uses DNA sequencing-based methods as an initial step. Examples of work that would be within scope include pilot studies using emerging technology like multi-omics, or that evaluate the effectiveness of using molecular methods like RNA-seq or methylation as an initial step. Technologies that show potential in these proof of concept studies will be integrated into the activities of the Technology Integration Center in later years.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in 2025 with an expected application due date in 2026. This NOFO will utilize the U01 activity code.

This United States Clinical Trials opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyNational Institutes of Health
CountryUnited States
CategoryClinical Trials
Estimated value$7.5M
PublishedJune 18, 2026
Procurement stageRequest for Proposal (RFP)
Response dueOctober 30, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: U.S. Government (Simpler.Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
Clinical and Translational Science Award (UM1 Clinical Trial Optional)
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)

See every United States Clinical Trials opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Clinical Trials intelligence report in your inbox

A personalized report on United States Clinical Trials opportunities, emailed in 5-10 minutes. One per month, no account needed.